This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
H1N1 VLP Vaccine
Mitsubishi Tanabe Pharma Corporation
Drug Names(s): Quadrivalent seasonal influenza vaccine
Description: Medicago's H1N1 vaccine was formulated to protect against the seasonal influenza virus. It is manufactured in Nicotiana benthamiana, a relative of the tobacco plant, using the Company's proprietary VLP technology.
VLPs have several advantages over traditional influenza vaccines. They resemble the virus, allowing them to be recognized readily by the body's immune system, however, they lack the core genetic material making them non-infectious and unable to replicate.
Medicago and Philip Morris
In September 2012, Medicago announced the signing of a licensing agreement with Philip Morris Products SA (PMP), a subsidiary of Philip Morris International Inc. Under the agreement, Medicago grants PMP an exclusive license to develop, commercialize and manufacture Medicago's pandemic and seasonal influenza vaccines for China. Medicago will receive an upfront payment of US$4.5 million from PMP. In addition, Medicago is eligible to receive development milestone payments totalling US$7.5 million, as well as royalty payments on any future sales of pandemic and seasonal influenza vaccines by PMP in China which utilize the Medicago technologies.
Medicago and Mitsubishi Tanabe
In July 2013, Medicago announced that it has entered into a definitive arrangement agreement with Mitsubishi Tanabe (MTPC) whereby MTPC will acquire all of the issued and outstanding common shares of Medicago, other than the Shares currently held by Philip...See full deal structure in Biomedtracker
Partners: Philip Morris International Inc.
H1N1 VLP Vaccine News
Additional information available to subscribers only: